Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
In case of orphan drugs applicability of the standard health technology assessment (HTA) process is limited due to scarcity of good clinical and health economic evidence. Financing these premium priced drugs is more controversial in the Central and Eastern European (CEE) region where the public funding resources are more restricted, and health economic justification should be an even more important aspect of policy decisions than in higher income European countries.



To explore and summarize the recent scientific evidence on value drivers related to the health technology assessment of ODs with a special focus on the perspective of third party payers in CEE countries. The review aims to list all potentially relevant value drivers in the reimbursement process of orphan drugs.



A systematic literature review was performed; PubMed and Scopus databases were systematically searched for relevant publications until April 2015. Extracted data were summarized along key HTA elements.



From the 2664 identified publications, 87 contained relevant information on the evaluation criteria of orphan drugs, but only 5 had direct information from the CEE region. The presentation of good clinical evidence seems to play a key role especially since this should be the basis of cost-effectiveness analyses, which have more importance in resource-constrained economies. Due to external price referencing of pharmaceuticals, the relative budget impact of orphan drugs is expected to be higher in CEE than in Western European (WE) countries unless accessibility of patients remains more limited in poorer European regions. Equity principles based on disease prevalence and non-availability of alternative treatment options may increase the price premium, however, societies must have some control on prices and a rationale based on multiple criteria in reimbursement decisions.



The evaluation of orphan medicines should include multiple criteria to appropriately measure the clinical added value of orphan drugs. The search found only a small number of studies coming from CEE, therefore European policies on orphan drugs may be based largely on experiences in WE countries. More research should be done in the future in CEE because financing high-priced orphan drugs involves a greater burden for these countries.
Department of Health Policy and Health Economics, Institute of Economics, Faculty of Social Sciences, Eötvös Loránd University, Pázmány Péter sétány 1/A, 1117, Budapest, Hungary.
Tamás
T
Zelei
Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Tömő u. 25-29, 1083, Budapest, Hungary.
Mária J
MJ
Molnár
Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Tömő u. 25-29, 1083, Budapest, Hungary.
Márta
M
Szegedi
Department of Health Policy and Health Economics, Institute of Economics, Faculty of Social Sciences, Eötvös Loránd University, Pázmány Péter sétány 1/A, 1117, Budapest, Hungary. kalo@tatk.elte.hu.|Syreon Research Institute, Mexikói út 65/A, 1142, Budapest, Hungary. kalo@tatk.elte.hu.
Zoltán
Z
Kaló
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005060:Europe; D006801:Humans; D009965:Orphan Drug Production / Q000191:economics*; D035583:Rare Diseases / Q000188:drug therapy*; D013673:Technology Assessment, Biomedical / Q000379:methods*
Central and Eastern Europe; Cost effectiveness; Drug approval; Economic evaluation; Orphan drug; Rare disease; Technology assessment